Sandoz launches Pyzchiva in U.S.

Sandoz launches biosimilar Pyzchiva in USA
Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, the medicine is commercially available to patients across the USA.
Sandoz launches biosimilar Pyzchiva in U.S. for all approved Stelara indications
Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the U.
Sandoz launches Pyzchiva in the U.S.
Sandoz (SDZNY) announced the launch of Pyzchiva in the U.S. The medicine is now commercially available to patients across the U.S. Discover
Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients
Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge
Samsung Bioepis Announces US Launch of PYZCHIVA(R) (ustekinumab-ttwe), Biosimilar to Stelara
Samsung Bioepis Co., Ltd. today announced that PYZCHIVA(R) (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been appr
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy
Sandoz family foundation offers $3 billion worth of Novartis shares
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss ...
STAT21h
J&J sues Samsung over a contract breach for a Stelara biosimilar
As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...
Rapid City Journal6h
A Show That Inspires now open in Sandoz Center
More than 60 years of work by local artist Dave Nixon is exhibited in the Mari Sandoz High Plains Heritage Center.
Sandoz to pay $275 million to settle drug price-fixing case
Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...
Daily5d
Drug price fixation: Sandoz to pay $275 million to settle case
Sandoz has agreed to pay $275 million to settle claims that it conspired with competitors to fix prices illegally.Attorneys ...
Zawya1d
Egyptian Drug Authority, Sandoz discuss oncology drug localisation
The meeting served as a platform to announce Sandoz Egypt’s new regional head and was held within the framework of strengthening the strategic cooperation between the EDA and Sandoz in the pharmaceuti ...
Michel Robidoux of Sandoz Canada Elected Chair of Canadian Generic Pharmaceutical Association
The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the unanimous election of Michel Robidoux, ...